Amplia Therapeutics Limited (ATX:ASX)

29.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $31.23M
Last trade 16.10pm 22/01/2021 20mins delayed

Latest Announcements

11/01/2021ATXAmplia Therapeutics Limited
160
MCap
17/12/2020ATXAmplia Therapeutics Limited
1,796
MCap
02/12/2020 Price SensitivePSATXAmplia Therapeutics Limited
408
MCap
27/11/2020 Price SensitivePSATXAmplia Therapeutics Limited
217
MCap
24/11/2020ATXAmplia Therapeutics Limited
967
MCap
02/11/2020ATXAmplia Therapeutics Limited
197
MCap
29/10/2020 Price SensitivePSATXAmplia Therapeutics Limited
602
MCap
21/10/2020ATXAmplia Therapeutics Limited
5,164
MCap

Company Overview

Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3).

ATX in the news

Amplia Therapeutics (ASX:ATX) receives ethics approval for phase one FAK trial

Amplia Therapeutics’ (ASX:ATX) preliminary toxicology supports phase one clinical trial

Amplia (ASX:ATX) on the way to FDA assistance following second orphan drug designation

Search Previous Announcements